

ISO/TR 12417-2:2022-07 (E)

Cardiovascular implants and extracorporeal systems - Vascular device-drug combination products - Part 2: Local regulatory information

Contents		Page
Foreword		v
Introduction		vi
1	Scope	1
2	Normative references	1
3	Terms and definitions	1
4	Information on device- and drug-related aspects -- Applicable documents for local guidance	4
4.1	General	4
4.2	Australia	4
4.2.1	General	4
4.2.2	Australia: Managing changes	5
4.2.3	Australia: Clinical evaluation requirements	5
4.2.4	Australia: Audit requirements	5
4.3	Brazil	5
4.3.1	Brazil: Managing changes	5
4.3.2	Brazil: Clinical evaluation requirements	6
4.3.3	Brazil: Audit requirements	6
4.4	Canada	6
4.4.1	Canada: Managing changes	6
4.4.2	Canada: Clinical evaluation requirements	6
4.4.3	Canada: Audit requirements	6
4.5	European Union (EU)	6
4.5.1	EU: Managing changes	6
4.5.2	EU: Material inclusion and labelling requirements	7
4.5.3	EU: Clinical evaluation requirements	7
4.5.4	EU: Audit requirements	7
4.6	India	7
4.6.1	India: Managing changes	7
4.6.2	India: Clinical evaluation requirements	8
4.6.3	India: Audit requirements	8
4.7	Japan	8
4.7.1	Japan: Managing changes	8
4.7.2	Japan: Clinical evaluation requirements	8
4.7.3	Japan: Audit requirements	8
4.8	People's Republic of China (PRC)	8
4.8.1	PRC: Managing changes	8
4.8.2	PRC: Clinical evaluation requirements	9
4.8.3	PRC: Audit requirements	10
4.9	Russia	10
4.9.1	Russia: Managing changes	10
4.9.2	Russia: Clinical evaluation requirements	10
4.9.3	Russia: Audit requirements	10
4.10	United States of America (USA)	10
4.10.1	USA: Managing changes	10
4.10.2	USA: Clinical evaluation requirements	11
4.10.3	USA: Audit requirements	11

5	Managing changes that can impact the DCP	12
5.1	General	12
5.2	Change evaluation	12
5.2.1	Identify changes	12
5.2.2	Risk evaluation	13
5.2.3	Guidance for change evaluation	13
5.2.4	Pre-market	14
5.3	Interactions with region-specific regulatory authorities -- Post-commercialization	14
	Bibliography	22